Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genkyotex,a developer of NOX inhibitors, has announced the successful completion of Phase Ia study with GKT13783, an inhibitor that targets NOX1 and NOX4 enzymes.
Subscribe to our email newsletter
The study showed that GKT137831 is safe and well tolerated following oral administration of single doses in 36 healthy subjects.
Pharmacokinetic analysis demonstrates good dose proportional exposure to GKT137831 and confirms that oral dosing of GKT137831 once or twice a day is a suitable regimen for further studies.
As part of the studies, the inhibitor is initially being studied for the treatment of diabetic nephropathy.
The company is currently conducting a multiple dose Phase Ib study.
Genkyotex chief medical officer Philippe Wiesel said the results to date of these studies first in human study have been very encouraging and doses tested have been well tolerated, with no dose limiting side effects.
"Our Phase Ib study continues and if successful we aim to start Phase II studies in diabetic nephropathy around the end of 2012," Philippe added.